Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01548274
Recruitment Status : Unknown
Verified March 2012 by Keiko Naruse, Aichi Gakuin University.
Recruitment status was:  Recruiting
First Posted : March 8, 2012
Last Update Posted : March 8, 2012
Information provided by (Responsible Party):
Keiko Naruse, Aichi Gakuin University

Brief Summary:
The purpose of this study is to evaluate the effects of Sarpogrelate in endothelial progenitor cells of patients with atherosclerosis.

Condition or disease Intervention/treatment Phase
Atherosclerosis Drug: Sarpogrelate Not Applicable

Detailed Description:
Endothelial progenitor cells play an important role in vasculogenesis and vascular repair. Sarpogrelate, a inhibitor of HT2A, is used an an anti-platelet drug, however, a direct effect in vascular cells is supposed.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells
Study Start Date : October 2010
Estimated Primary Completion Date : October 2012
Estimated Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis

Intervention Details:
  • Drug: Sarpogrelate
    Sarpogrelate 300mg/day

Primary Outcome Measures :
  1. The number and function of endothelial progenitor cells [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with atherosclerosis

Exclusion Criteria:

  • Patients with high risk of bleeding
  • Patients with pregnancy
  • Patients with allergic reaction of Salpogrelate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01548274

Aichi-Gakuin University Recruiting
Nagoya, Aichi, Japan, 464-8651
Contact: Keiko Naruse, M.D., Ph.D.    +81-52-759-2111 ext 5369   
Sponsors and Collaborators
Aichi Gakuin University

Responsible Party: Keiko Naruse, Associate professor, Aichi Gakuin University Identifier: NCT01548274     History of Changes
Other Study ID Numbers: AGU-65
First Posted: March 8, 2012    Key Record Dates
Last Update Posted: March 8, 2012
Last Verified: March 2012

Keywords provided by Keiko Naruse, Aichi Gakuin University:
endothelial progenitor cells

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Physiological Effects of Drugs